Bulk Active Ingredients from Pfizer CentreSource - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pfizer CentreSource (PCS) has an established reputation for providing high quality Bulk Active Ingredients to the global fine chemicals marketplace. Our broad range of corticosteroids and hormonal steroids is used in a wide variety of sterile-manufacturing-packaging indications. Pfizer is a leading supplier of fine chemicals, steroid APIs, and steroid intermediates. Pfizer’s strength among steroid API suppliers is derived from our backward-integrated production platform based on soy sterol bioconversion and innovative chemical synthesis.

PCS corticosteroid offerings include dexamethasone, hydrocortisone, hydrocortisone acetate, prednisone, and spironolactone.

Hormonal Steroid products from PCS include: progesterone, megestrol acetate, testosterone, testosterone cypionate, and testosterone propionate.

PCS also supplies two grades of neomycin sulfate antibiotic, including Neomycin Sulfate Powder USP/EP and Neomycin Sulfate Micronized USP/EP.

For advanced intermediates, Pfizer’s unique GMP compliant process utilizes soybean-derived sterols and proprietary fermentation processes to create a very broad intermediate platform. This is done at a large scale, a far more efficient process than operations used by competing steroid manufacturers.

Pfizer CentreSource (PCS)
Website:  www.pfizercentresource.com
Email: Kenneth.F.Ball@pfizer.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here